Fluoroquinolones can penetrate in the lung better than aminoglycosides such as gentamicin, tobramycin, or amikacin, and have less potential for nephrotoxicity making them a good choice for the treatment of susceptible isolates of Pseudomonas aeruginosa and other Gram-negative bacteria. Their role in empiric therapy should be reserved for patients with a low-risk for MDR pathogens or as combination therapy with a β-lactam for Pseudomonas aeruginosa (45).